Need for additional capital
The company expects continued losses and has not generated product-sales revenue, so it must fund trials and manufacturing externally.
- Scope
- Equity, debt, collaborations, licensing
- Materiality
- high
MeiraGTx Holdings plc
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease, central nervous system disorders, and other serious conditions. The company also operates manufacturing capabilities in the UK and Ireland, which it uses to support its own pipeline and third-party or collaboration-related supply and testing activities.
−114,8 %
−140,3 %
+144,6 %
0.75
0.75
| % | |
|---|---|
| Ophthalmology gene therapies | 35% AAV-based product candidates targeting inherited retinal diseases and other eye disorders. |
| Neurology gene therapies | 25% Locally delivered genetic medicines for central nervous system indications, including AAV-GAD and AAV-BDNF. |
| Manufacturing services | 25% Internal and collaboration-linked manufacturing of viral vectors and gene therapy materials. |
| Quality control and testing services | 10% Release, stability, and QC testing for commercial and investigational medicinal products. |
| Collaboration and supply agreements | 5% Upfront, milestone, and supply-related arrangements with pharmaceutical and biotech partners. |
MeiraGTx primarily serves pharmaceutical and biotech collaborators that need gene therapy development, manufacturing,...
- Pharmaceutical collaboration partnersprimary
Partners that fund, co-develop, or commercialize gene therapy programs and buy supply/manufacturing commitments.
- Biotech and clinical development partnersprimary
Smaller developers that need AAV manufacturing, QC testing, and clinical supply for trials.
- Rare disease patients and physicianssecondary
Future end users of ophthalmology programs if approved, especially inherited retinal disease patients.
- Neurology treatment centerssecondary
Future clinical and commercial users of CNS gene therapies delivered through local administration.
The company is headquartered in the United States but its operating footprint is concentrated in the UK and Ireland,...
- •Headquartered in the United States with a global development footprint
- •Manufacturing and QC operations in London, United Kingdom
- •Shannon, Ireland site supports QC and clinical-trial manufacturing
- •UK/EU regulatory approvals are critical to manufacturing continuity
- •International commercialization would add pricing, privacy, and IP risk
MeiraGTx is focused on advancing its clinical pipeline while building the manufacturing and regulatory infrastructure...
01
Advance lead gene therapy programsshort-term
Clinical progress is the main path to value creation in a company with no approved products.
02
Scale manufacturing and QC capabilitiesmedium-term
Commercial success depends on reliable GMP supply, release testing, and regulatory compliance.
03
Secure collaboration funding and supply agreementsshort-term
Partnerships reduce financing burden and can create future revenue streams before product launch.
The company remains pre-commercial and has a history of operating losses, so its ability to fund development is a...
Manufacturing and supply-chain disruption
Gene therapy production depends on specialized facilities, plasmid supply, and GMP-compliant third parties.
- Scope
- Clinical and commercial supply
- Materiality
- high
Regulatory compliance failure
FDA, MHRA, EMA, and HPRA requirements govern manufacturing, testing, and commercialization.
- Scope
- Licenses, approvals, product release
- Materiality
- high
Clinical development failure
Pipeline value depends on proving safety and efficacy in rare disease and CNS indications.
- Scope
- Ophthalmology and neurology programs
- Materiality
- high
International commercialization complexity
Foreign markets can impose different reimbursement, privacy, and IP rules that raise launch friction.
- Scope
- Outside the US, UK, and EU
- Materiality
- medium
Collaboration and service revenue recognition
Can create quarter-to-quarter volatility in reported revenue
Related-party contract assets and deferred revenue
Affects timing of revenue and working capital
Share-based compensation
Impacts operating loss and cash flow reconciliation
Foreign currency translation
Moves other comprehensive loss and equity
Capitalized manufacturing and facility assets
Can affect depreciation, asset carrying values, and future impairment charges
REGENXBIO Inc.
RGNX · Biological Products, (No Diagnostic Substances)
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
4D Molecular Therapeutics, Inc.
FDMT · Biological Products, (No Diagnostic Substances)
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Tenaya Therapeutics, Inc.
TNYA · Biological Products, (No Diagnostic Substances)
Tenaya Therapeutics is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for heart disease.
RetinalGenix Technologies Inc.
RTGN · Surgical & Medical Instruments & Apparatus
: 28/04/2026